Bruker (NASDAQ:BRKR) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Bruker (NASDAQ:BRKR) issued its earnings results on Thursday. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06), FiscalAI reports. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The business had revenue of $977.20 million for the quarter, compared to the consensus estimate of $964.61 million. During the same period in the previous year, the firm earned $0.76 EPS. The company’s revenue was down .2% compared to the same quarter last year. Bruker updated its FY 2026 guidance to 2.100-2.150 EPS.

Here are the key takeaways from Bruker’s conference call:

• FY2026 guidance — Bruker expects reported revenue of $3.57–$3.60B (4%–5% growth), 1%–2% organic growth, a 250–300 bps non‑GAAP operating margin improvement, and 15%–17% non‑GAAP EPS growth (23%–25% CER), while acknowledging an ~8% currency EPS headwind.
• Strong Q4 cash and deleveraging — Q4 operating cash flow was ~ $230M with free cash flow of $207M, the company repaid ~$145M of debt and finished 2025 with ~ $300M in cash and a leverage ratio of ~3.1.
• Order momentum and strategic wins — BSI book‑to‑bill was >1.0 for two consecutive quarters with ~7 months of BSI backlog, strong semi‑metrology orders, double‑digit spatial biology orders, and >$500M in multi‑year BEST superconducting‑wire agreements booked.
• Lingering headwinds and near‑term weakness — 2025 organic revenue declined (full year down 3.7%, Q4 organic down 5.1%), margins were pressured by tariffs, unfavorable mix and currency (gross margin down ~310 bps in Q4), and management expects Q1 2026 organic revenue to decline mid‑single digits before recovery later in the year.

Bruker Trading Down 14.1%

BRKR stock traded down $5.97 during trading on Thursday, hitting $36.46. 3,600,586 shares of the company traded hands, compared to its average volume of 2,537,495. The company has a 50-day moving average of $47.37 and a 200-day moving average of $40.57. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.91 and a current ratio of 1.85. Bruker has a 1 year low of $28.53 and a 1 year high of $56.22. The firm has a market capitalization of $5.54 billion, a PE ratio of -227.42, a P/E/G ratio of 5.47 and a beta of 1.19.

Insider Activity

In related news, VP Mark Munch sold 7,000 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $55.00, for a total transaction of $385,000.00. Following the completion of the sale, the vice president directly owned 128,443 shares in the company, valued at $7,064,365. This represents a 5.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 27.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

Several hedge funds have recently made changes to their positions in the business. Los Angeles Capital Management LLC bought a new position in Bruker in the 4th quarter worth $26,000. Allworth Financial LP grew its holdings in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the period. Parallel Advisors LLC increased its stake in shares of Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Bruker by 51.5% in the second quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock worth $114,000 after acquiring an additional 942 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Bruker by 56.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,172 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 1,497 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on BRKR shares. Wells Fargo & Company boosted their price objective on shares of Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Rothschild & Co Redburn set a $60.00 price target on shares of Bruker in a report on Thursday, November 20th. Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. UBS Group raised their target price on shares of Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $53.23.

Bruker News Roundup

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Q4 revenue beat expectations — Bruker reported $977.2M in revenue vs. consensus of $964.6M, showing top-line resilience. Bruker’s (NASDAQ: BRKR) Q4 CY2025 sales beat estimates
• Positive Sentiment: FY2026 revenue guidance raised/confirmed aboveStreet — company set FY revenue around $3.6B, above consensus ~ $3.5B, which supports growth expectations for the year. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Commercial partnership in India expands spatial biology footprint — a collaboration with Premas Life Sciences may help adoption and revenue growth in a key market. Premas Life Sciences Partners with Bruker Spatial Biology to Strengthen Advanced Tissue Research in India
• Neutral Sentiment: Revenue was essentially flat year-over-year (down ~0.2%), indicating stability but limited organic growth in the quarter. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Company posted materials (press release, slide deck, conference call) for deeper review — useful for investors but not market-moving by itself. View Press Release / Slide Deck
• Negative Sentiment: EPS missed and profitability weakened — Q4 EPS $0.59 vs. consensus $0.65 and down from $0.76 a year ago; net margin was slightly negative, which pressured investor confidence. Bruker (BRKR) Q4 Earnings Miss Estimates
• Negative Sentiment: FY2026 EPS guidance came in slightly below consensus — management guided EPS of $2.10–$2.15 versus street ~ $2.13, which, combined with the EPS miss, likely amplified the selloff despite the revenue guidance. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Market reaction: high volume selling — investors appear to have focused on the EPS miss and the modest EPS guidance shortfall, driving a sharp decline in the share price. (See company filings and coverage above for details.)

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.